Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

68Ga(Gallium)-DOTATATE Positron Emission Tomography (PET)/MRI in the Diagnosis and Management of Somatostatin Receptor Positive Central Nervous System CNS Tumors

Next Previous
Trial Profile

68Ga(Gallium)-DOTATATE Positron Emission Tomography (PET)/MRI in the Diagnosis and Management of Somatostatin Receptor Positive Central Nervous System CNS Tumors

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gallium 68-DOTATATE (Primary)
  • Indications CNS cancer; Haemangioblastoma; Meningioma; Neuroblastoma; Paraganglioma; Pituitary adenoma
  • Focus Diagnostic use
  • Acronyms DOMINO-START

Most Recent Events

  • 27 Feb 2023 Planned number of patients changed from 98 to 200.
  • 27 Feb 2023 Planned End Date changed from 30 Dec 2022 to 31 Dec 2038.
  • 27 Feb 2023 Planned primary completion date changed from 30 Dec 2022 to 31 Dec 2038.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top